


Name	Sung Yong Lee	
Country	Republic of Korea	
Organization	Korea University Guro Hospital	
Current Position	Professor	

Educational Background

1989.3-1995.2	MD degree from Korea University College of Medicine
1998.3-2000.2	Master degree from Korea University, Graduate School, Seoul, Korea
2003.9-2006.2	Ph.D. degree from Korea University, Graduate School, Seoul, Korea

Professional Experiences

1995.3-1996.2	Internship in Korea University Guro Hospital
1996.2-2000.2	Residency in Internal Medicine, Korea University Anam Hospital
2000.3-2003.4	Served in Korean Army
2003.5-2004.4	Clinical Instructor at Division of Pulmonology Dept. of Internal Medicine, Korea University Guro Hospital
2004.4-2006.2	Clinical Assistant Professor at Division of Pulmonology Dept. of Internal Medicine, Korea University Guro Hospital
2006.3- 2009.2	Assistant Professor at Division of Pulmonology Dept. of Internal Medicine, Korea University Guro Hospital
2009.3-2015.2	Associate Professor at Division of Pulmonology Dept. of Internal Medicine, Korea University Guro Hospital
2011.3-2013.2	Research Fellow at Department of Pathology, Johns Hopkins
2015.3-	Professor at Division of Pulmonary, Allergy, and Critical Care Medicine Chief of Division of Pulmonary, Allergy, and Critical Care Medicine

Professional Organizations

- Member of Korean Society of Internal Medicine
- Member of Korean Academy of Tuberculosis and Respiratory Disease
- Member of Korean Association for the Study of Lung Cancer
- Member of Asian Pacific Society of Respirology
- Member of American Association for Cancer Research
- Member of International Association for the Study of Lung Cancer

Main Scientific Publications

1. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial). Juwhan Choi, Jeong Eun Lee, Chang-Min Choi, In-Jae Oh, Kye Young Lee, Tae Won Jang, Seung Hyeun Lee, Eun Young Kim, Dong Won Park, Sun Hyo Park, Sung Yong Lee. *Thorac Cancer*. 2022. Oct
2. Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer. Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min Ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee. *Cancer Res Treat*. 2022 Aug
3. Use of thyroid transcription factor 1 and napsin A to predict local failure and survival after Gamma Knife radiosurgery in patients with brain metastases from lung adenocarcinoma. Haewon Roh, Sung Yong Lee, Jinhwan Lee, Soon-Young Hwang, Jong Hyun Kim. *J Neurosurg*. 2022. Aug 12;1-11
4. The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases. Juan Zhou, Yinfei Wu, Mengqing Xie, Yujia Fang, Jing Zhao, Sung Yong Lee, Yunjoo Im, Lingyun Ye, Chunxia Su. *Transl Lung Cancer Res*. 2022 Apr;11:656-669
5. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. Mi-Hyun Kim, Chang Min Choi, Sung Yong Lee, Cheol Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon, Tae Won Jang. *Anticancer Res*. 2022 Mar;42:1615-1622
6. Genetic Characteristics Associated With Drug Resistance in Lung Cancer and Colorectal Cancer Using Whole Exome Sequencing of Cell-Free DNA. Jong Won Lee, Young Soo Park, Jung Yoon Choi, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Boyeon Kim, Saet Byeol Lee, Sung Yong Lee, Jungmin Choi, Yeul Hong Kim. *Front Oncol*. 2022 Mar 24;12:843561
7. Usefulness of Pulmonary Rehabilitation in Non-small Cell Lung Cancer Patients Based on Pulmonary Function Tests and Muscle Analysis Using Computed Tomography Images. Juwhan Choi, Zepa Yang, Jinhwan Lee, Jun Hee Lee, Hyun Koo Kim, Hwan Seok Yong, Sung Yong Lee. *Cancer Res Treat* 2021 Oct. 20
8. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer. Hyun-Seock Shin, Juwhan Choi, Jinhwan Lee, Sung Yong Lee. *Cancer Res Treat* 2021 Sep. 10

-
9. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang. *BMC Cancer*. 2021 Jan 11;21(1):52
 10. Effects of a Mixture of Ivy Leaf Extract and Coptidis rhizome on Patients with Chronic Bronchitis and Bronchiectasis. Goohyeon Hong, Yu-Il Kim, Seoung Ju Park, Sung Yong Lee, Jin Woo Kim, Seong Hoon Yoon, Keu Sung Lee, Min Kwang Byun, Hak-Ryul Kim, Jaeho Chung. *Int J Environ Res Public Health*. 2021 Apr 12;18(8):4024.
 11. Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study). Seung Hyeun Lee, Cheol-Kyu Park, Sung Yong Lee, Chang-Min Choi. *Thorac Cancer*. 2021 Apr;12(8):1264-1268.
 12. Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting. Yunha Nam, Ho Cheol Kim, Young-Chul Kim, Seung Hun Jang, Kye Young Lee, Shin Yup Lee, Sang Hoon Lee, Sung Yong Lee, Seong Hoon Yoon, Jeong-Seon Ryu, Tae Won Jang, Yoon Soo Chang, Seung Joon Kim, Chan Kwon Park, Jeong Eun Lee, Chi Young Jung, Chang-Min Choi. *Thorac Cancer*, 2021 Mar;12(6):890-898
 13. Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A. Cheol-Kyu Park, Sung-Yong Lee, Jae Cheol Lee, Chang-Min Choi, Shin Yup Lee, Tae-Won Jang, In-Jae Oh, Young-Chul Kim. *Thorac Cancer*. 2020 Dec 3
 14. Clinical Efficacy of Adjuvant Chemotherapy in Stage IB (<4cm) Non-Small Cell Lung Cancer Patients with High-Risk Factors. Juwhan Choi, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Jae Jeong Shim, Sue In Choi, Dong Won Park, Chan Kwon Park, Eun Joo Kang, Hwan Seok Yong, Bong Kyung Shin, Hyun Koo Kim, Sung Yong Lee. *Korean J Intern Med* 2020 Aug 21
 15. Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Sun Min Lim, Sang-We Kim, Byoung Chul Cho, Jin Hyung Kang, Myung-Ju Ahn, Dong-Wan Kim, Young-Chul Kim, Jin Soo Lee, Jong-Seok Lee, Sung Yong Lee, Keon Uk Park, Ho Jung An, Eun Kyung Cho, Tae Won Jang, Bong-Seog Kim, Joo-Hang Kim, Sung Sook Lee, Im-li Na, Seung Soo Yoo, Ki Hyeong Lee. *Cancer Res Treat* 2020 May 15
 16. Relationship between Particulate Matter (PM10) and Airway Inflammation Measured with Exhaled Nitric Oxide Test in Seoul, Korea. Choi J, Sim JK, Oh JY, Lee YS, Hur GY, Lee SY, Shim JJ, Moon JY, Min KH. *Can Respir J*. 2020 Mar 17;2020
-